SAS Output

22-SEP-2017 18:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1320-Adv, BRAF mut, Inter v Contin 1 Y 1 Lead-in Continuous Dosing 280 171 59 34 14 5 1 09/19/2014 246 110
            171 59 34 14 5 1      
 
    2 Y 2 Continuous Dosing 280 70 23 16 7 2 1 09/19/2014    
        3 Intermittent Dosing   70 25 11 6 4 2      
            140 48 27 13 6 3      
 
  S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475 1 N 1 Tissue for PD-L1 testing 1378 1426 992 470 213 0 0 11/10/2015 392 172
            1426 992 470 213 0 0      
 
    2 Y 2 FDA approved regimen 1378 678 488 243 118 21 1 11/10/2015    
        3 MK-3475 (Pembrolizumab)   667 484 243 110 20 0      
            1345 972 486 228 41 1      
 
  S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 77 3 3 2 2 0 0 02/06/2017 73 31
            3 3 2 2 0 0      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   19 12 4 3 2 2 11/03/2015 336 143
            19 12 4 3 2 2      
 
    2 E Total Registrations   5 4 2 2 1 0 11/03/2015    
            5 4 2 2 1 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim 1 E Total Registrations   36 27 18 4 0 0 03/25/2016 299 123
            36 27 18 4 0 0      
 
No E3612-MELAN,Adv Ipilimumab±Bevacizumab 1 E Total Registrations   6 2 1 1 1 0 02/16/2015 138 50
            6 2 1 1 1 0      
 

22-SEP-2017 18:10

MELAN Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1616 MELAN,, Adv, Ipilimumab ± Nivolumab 1 Randomization 17-Jul-17